10月21日，云顶新耀盘中上涨5.03%，报35.5港元，成交额5321.4万港元。
消息面上，市场继续交易公司自主mRNA平台全球临床开发提速预期。
近期公司引入两名前莫德纳核心科学家，已披露其将重点推动mRNA技术平台在美国的临床开发，并与中国研发团队协作。与此同时，个性化肿瘤治疗性疫苗EVM16已交出首批人体数据，通用现货型肿瘤相关抗原疫苗EVM14正推进临床，强化平台进入临床验证阶段的信号。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.